High FGFR1-4 mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer

amplification ( amp) is recurrent in metastatic breast cancer (MBC) and is associated with resistance to endocrine therapy and CDK4/6 inhibitors (CDK4/6is). Multi-tyrosine kinase inhibitors (MTKIs) and selective pan-FGFR inhibitors (FGFRis) are being developed for amp breast cancer. High-level ampli...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Clinical cancer research 2022-01, Vol.28 (1), p.137-149
Hauptverfasser:	Sánchez-Guixé, Mònica, Hierro, Cinta, Jiménez, José, Viaplana, Cristina, Villacampa, Guillermo, Monelli, Erika, Brasó-Maristany, Fara, Ogbah, Zighereda, Parés, Mireia, Guzmán, Marta, Grueso, Judit, Rodríguez, Olga, Oliveira, Mafalda, Azaro, Analía, Garralda, Elena, Tabernero, Josep, Casanovas, Oriol, Scaltriti, Maurizio, Prat, Aleix, Dienstmann, Rodrigo, Nuciforo, Paolo, Saura, Cristina, Graupera, Mariona, Vivancos, Ana, Rodon, Jordi, Serra, Violeta
Format:	Artikel
Sprache:	eng
Schlagworte:	Breast Neoplasms Female Humans Protein Kinase Inhibitors - pharmacology Protein Kinase Inhibitors - therapeutic use Receptor Protein-Tyrosine Kinases - genetics Receptor Protein-Tyrosine Kinases - metabolism RNA, Messenger - biosynthesis RNA, Messenger - genetics Signal Transduction
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!